Claim Missing Document
Check
Articles

Found 2 Documents
Search

Knowledge Level of COVID-19 Prevention in Banjar Gambang Communities, Seraya Village, Karangasem, Indonesia Sasmana, I Gede Aswin Parisya; Wihandani, Desak Made; Halim, Wilson; Jaya, Ni Komang Ayu Amanda Setiari; Atmaja, Made Ayu Kurniati; Edgar, Christine; Sutedja, Jane Carissa; Mamangdean, Christo Timothy; Wijaya, Grace Veronika; Kusumadewi, Made Dea Avrilia
Althea Medical Journal Vol 10, No 2 (2023)
Publisher : Faculty of Medicine Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15850/amj.v10n2.2857

Abstract

Background: Problems to COVID-19 are closely related to the level of knowledge and community prevention. Therefore, to overcome COVID-19, increased knowledge and prevention are needed. This study aimed to evaluate the correlation between prevention and knowledge level about COVID-19.Methods: A cross-sectional study using a convenience sampling approach was conducted in Banjar Gambang, Karangasem, Indonesia, in April 2022. The knowledge level and preventive behavior towards COVID-19 were measured using the COVID-19 Preventive Behaviors Index (CPBI) and the knowledge, attitudes, and practice toward COVID-19 (KAPCOV-19) questionnaire. The data were analyzed using SPSS software version 26.0.Results: A total of 52 respondents were included, who had excellent level of knowledge (44.2%) and moderate prevention behaviour (48.1%). A strong and significant correlation was found between the preventive index and the knowledge levels of COVID-19 (r = 0.548; p<0.001). The level of knowledge was significantly related to the level of preventive behavior (p= 0.003), as well as the education level (r = 0.323; p = 0.02) and age (r= -0.346; p=0.012).Conclusion: The level of knowledge and the individual prevention behavior toward COVID-19 are directly proportional to each other. Those who have a low level of knowledge, might affect their prevention behavior toward COVID-19, therefore, personalized socialization of COVID-19 prevention is still required.
Pre-Targeting Bispecific Antibody (BSAB) and Pegylated Liposomal Drug Nanocarrier as Management of Acute Lymphoblastic Leukemia (ALL) In Pediatrics Mareska, Viona; Halim, Wilson; Sadeva , Gede Krishna Arim
Eduvest - Journal of Universal Studies Vol. 5 No. 3 (2025): Eduvest - Journal of Universal Studies
Publisher : Green Publisher Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59188/eduvest.v5i3.1768

Abstract

Acute lymphoblastic leukemia (ALL) is a neoplastic condition commonly found in pediatric patients especially that involve B cell (B-ALL). Current treatments revolve around immunotherapy approaches such as Chimeric-Antigen Receptor T-cell (CAR-T) and tyrosine kinase inhibitor (TKI). However, flaws in both methods such as low pharmacokinetics, technical limitations, inability to recognize more than one antigen and other side effects remain a predicament to be solved. “immunotherapy”, “pediatry”, “b-all”, “bispesific antibody” and “PEGylated liposomal” were the keywords applied to scientific online databases, such as ScienceDirect, PubMed, dan Researchgate. A total of 25 journals were screened, reviewed and utilized with utmost precision to construct a literature review. Preparation of targeting bispesific antibody (BsAb) is constructed through the formation of chemical bond between the anti-mPEG scFV and CD20, whereas PEGylated liposomal drug nanocarriers is prepared through a covalent bonding chemical reaction. PEGylated drug nanocarriers has nontoxic, immunogenicity, antigenicity, and long half-life properties that increases both the pharmacokinetics and pharmacodynamics of anticancer drugs like chemotherapy through increased distribution, accumulation and decrease elimination of the drugs. BsAb will specifically target cancer-specific antigens, such as CD20 in cancer cells to initiate adaptive immune responses. Additionally, the antibody dependent endocytosis properties are a vital part in cancer therapy to increase cellular uptake of the liposome. All in all, the combination of bispesific antibody (BsAb) PEGylated liposomal drug nanocarriers towards B-ALL shows great promise towards the management of B-ALL in pediatric patients.